Compare AbbVie Inc (ABBV) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Rocket Lab USA Inc — how do they compare? AbbVie Inc trades at $248.8 (market cap $441.94B), while Rocket Lab USA Inc trades at $80.48 (market cap $50.01B). The key difference: AbbVie Inc is far larger — about 8.8× Rocket Lab USA Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| ABBV | RKLB | |
|---|---|---|
Market Cap | $441.94B | $50.01B |
Sector | Health | Technology |
52-Week High | $263.58 | $150.23 |
52-Week Low | $197.38 | $39.48 |
Enterprise Value | $506.19B | $47.84B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Rocket Lab (RKLB) trades at $81.06, up 1.27% today, with a bullish technical signal from moving averages and a record $2.36 billion backlog supporting growth. Revenue grew 60% year-over-year in Q2 2026, though net losses persist, and the stock is expensive with a P/S ratio of 60.8. Recent news highlights Neutron rocket development delays but strong contract wins.
The outlook is mixed: analyst consensus is bullish with a $118 price target, but profitability remains elusive until 2027. Key risks include execution on Neutron launches, high valuation, and cash burn. Upside depends on successful scaling and margin improvement from government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
